EP1929291A4 - Estriol therapy for autoimmune and neurodegenerataive diseases and disorders - Google Patents

Estriol therapy for autoimmune and neurodegenerataive diseases and disorders

Info

Publication number
EP1929291A4
EP1929291A4 EP06815626A EP06815626A EP1929291A4 EP 1929291 A4 EP1929291 A4 EP 1929291A4 EP 06815626 A EP06815626 A EP 06815626A EP 06815626 A EP06815626 A EP 06815626A EP 1929291 A4 EP1929291 A4 EP 1929291A4
Authority
EP
European Patent Office
Prior art keywords
neurodegenerataive
autoimmune
disorders
diseases
estriol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06815626A
Other languages
German (de)
French (fr)
Other versions
EP1929291A2 (en
Inventor
Rhonda R Voskuhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Priority to EP13005320.0A priority Critical patent/EP2698167A3/en
Priority to EP16000349.7A priority patent/EP3045177A1/en
Publication of EP1929291A2 publication Critical patent/EP1929291A2/en
Publication of EP1929291A4 publication Critical patent/EP1929291A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP06815626A 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders Ceased EP1929291A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13005320.0A EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
EP16000349.7A EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72097205P 2005-09-26 2005-09-26
US83352706P 2006-07-26 2006-07-26
PCT/US2006/037752 WO2007038636A2 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP13005320.0A Division EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
EP16000349.7A Division EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Publications (2)

Publication Number Publication Date
EP1929291A2 EP1929291A2 (en) 2008-06-11
EP1929291A4 true EP1929291A4 (en) 2010-12-22

Family

ID=37900442

Family Applications (3)

Application Number Title Priority Date Filing Date
EP06815626A Ceased EP1929291A4 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
EP13005320.0A Withdrawn EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
EP16000349.7A Withdrawn EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP13005320.0A Withdrawn EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
EP16000349.7A Withdrawn EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Country Status (5)

Country Link
EP (3) EP1929291A4 (en)
JP (1) JP2009510084A (en)
AU (1) AU2006294662A1 (en)
CA (1) CA2623839C (en)
WO (1) WO2007038636A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
WO2010050916A1 (en) * 2008-10-31 2010-05-06 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
CA2623905A1 (en) * 2005-09-26 2007-04-05 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerative diseases and disorders
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California Pregnancy hormone combination for treatment of autoimmune diseases
WO2009012569A1 (en) * 2007-07-20 2009-01-29 Stem Cell Therapeutics Corp. TREATING OR AMELIORATING A NEUROMFLAMMATORY OR DEMYELIMATING DISORDER WITH PROLACTIN AND INTERFERON-β
CN101835770B (en) 2007-10-26 2013-10-30 阿卡迪亚医药公司 Condensed compounds with activity at estrogen receptors
HUP0800414A2 (en) * 2008-07-04 2010-10-28 Pecsi Tudomanyegyetem Pharmaceutical combination
CA2830519A1 (en) 2011-03-22 2012-09-27 The Population Council, Inc. Myelin regeneration with androgens
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
EP3137087B1 (en) 2014-04-28 2023-09-06 The Regents of the University of California Estrogen combination for treatment of multiple sclerosis
EP3137088B1 (en) 2014-04-28 2023-08-30 The Regents of The University of California Pharmaceutical packaging for estriol therapy for the treatment of multiple sclerosis
EP3163284A4 (en) * 2014-06-27 2017-06-28 National University Corporation Nagoya University Embedding medium for specimen preparation, method for preparing curable base material non-penetrating specimen, method for preparing curable base material penetrating specimen, curable base material non-penetrating specimen, thin-slice-performance improver for frozen embedding medium, and frozen embedding medium
EP3189026B1 (en) * 2014-09-02 2020-07-22 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2016036719A1 (en) * 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
ES2957543T3 (en) 2014-09-29 2024-01-22 Univ California Compositions and methods to maintain cognitive function
WO2016160832A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of monitoring estriol therapy
CA3036511A1 (en) * 2016-09-12 2018-03-15 Steven Hoffman Compositions for treating dementia
US11285321B2 (en) * 2016-11-15 2022-03-29 The Regents Of The University Of California Methods and apparatuses for improving peripheral nerve function
EP3787633A1 (en) 2018-05-02 2021-03-10 Pantarhei Oncology B.V. Treatment of advanced estrogen receptor positive breast cancer
TW202124418A (en) * 2019-12-20 2021-07-01 比利時商埃斯特拉有限責任公司 Necroptosis modulators, screening methods and pharmaceutical compositions
CN113243332B (en) * 2020-02-07 2023-07-28 上海市东方医院（同济大学附属东方医院） Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9502921D0 (en) 1995-08-23 1995-08-23 Astra Ab New compounds
US6734211B1 (en) * 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
AR027878A1 (en) * 1999-11-05 2003-04-16 Wyeth Corp METHODS FOR IDENTIFYING AND USING AMILOID INHIBITING COMPOUNDS
AU2002237126A1 (en) * 2001-03-02 2002-09-19 Stem Cell Therapeutics Inc. Use of ovarian hormone for increasing neural stem cell number
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
JP4801868B2 (en) * 2002-02-25 2011-10-26 晃史 山口 Systemic lupus erythematosus disease suppressant
EP1358881A1 (en) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
CA2623905A1 (en) * 2005-09-26 2007-04-05 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIEWENGA E ET AL: "Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress", NEUROSCIENCE LETTERS, vol. 373, no. 3, 20 January 2005 (2005-01-20), LIMERICK, IE, pages 179 - 183, XP004690113, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2004.09.067 *
KUMAR D M ET AL: "Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity", FREE RADICAL BIOLOGY AND MEDICINE, vol. 38, no. 9, 1 May 2005 (2005-05-01), ELSEVIER SCIENCE, US, pages 1152 - 1163, XP025352119, ISSN: 0891-5849, [retrieved on 20050501] *
OFFNER, HALINA: "Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: Therapeutic implications for multiple sclerosis", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 78, no. 5, 28 October 2004 (2004-10-28), pages 603 - 624, XP002605593, ISSN: 0360-4012 *
PERRELLA, JOEL ET AL: "Protection of cortical cells by equine estrogens against glutamate-induced excitotoxicity is mediated through a calcium independent mechanism", BMC NEUROSCIENCE, vol. 6, 34, 10 May 2005 (2005-05-10), pages 17PP, XP002605592, ISSN: 1471-2202 *
SAMANTHA S SOLDAN ET AL: "Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol", JOURNAL OF IMMUNOLOGY, vol. 171, no. 11, 1 December 2003 (2003-12-01), AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, pages 6267 - 6268, XP008126547, ISSN: 0022-1767 *
WEN, YI ET AL: "Transient Cerebral Ischemia Induces Aberrant Neuronal Cell Cycle Re-entry and Alzheimer 's Disease-like Tauopathy in Female Rats", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 21, 24 February 2004 (2004-02-24), pages 22684 - 22692, XP002605887, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2623839A1 (en) 2007-04-05
EP2698167A2 (en) 2014-02-19
JP2009510084A (en) 2009-03-12
AU2006294662A1 (en) 2007-04-05
WO2007038636A3 (en) 2007-12-27
WO2007038636A2 (en) 2007-04-05
EP1929291A2 (en) 2008-06-11
EP3045177A1 (en) 2016-07-20
EP2698167A3 (en) 2014-03-05
CA2623839C (en) 2013-12-17

Similar Documents

Publication Publication Date Title
EP1929291A4 (en) Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
EP1928468A4 (en) Estriol therapy for autoimmune and neurodegenerative diseases and disorders
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ZA200702130B (en) Memantine for the treatment of childhood behavioral disorders
EP2010187A4 (en) Compounds for diseases and disorders
IL180251A0 (en) Methods and reagents for the treatment of metabolic disorders
GB0415112D0 (en) Therapeutic device
GB0419850D0 (en) Therapeutic agents
GB0416396D0 (en) Therapeutic agents
IL177155A0 (en) Therapeutic combinations
EP1838288A4 (en) Therapeutic materials and methods
GB0403780D0 (en) Therapeutic agents
IL186049A0 (en) Prophylactic or therapeutic agent for depression or anxiety disorders
ZA200700749B (en) Methods and reagents for the treatment of metabolic disorders
GB0419192D0 (en) Therapeutic agents
GB0407382D0 (en) Therapeutic methods and means
GB0403370D0 (en) Device for preventing retinal diseases
EP2059238A4 (en) Therapeutic compounds for diseases and disorders
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0419240D0 (en) Therapeutic device
GB0417939D0 (en) Therapeutic agents
GB0400193D0 (en) Therapeutic agents
GB0403779D0 (en) Therapeutic agents
GB0400196D0 (en) Therapeutic agents
GB0402918D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080331

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20101022BHEP

Ipc: A61K 31/568 20060101ALI20101022BHEP

Ipc: A61K 31/566 20060101ALI20101022BHEP

Ipc: A61K 31/565 20060101ALI20101022BHEP

Ipc: G01N 33/00 20060101AFI20080408BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20101118

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20151228